28 March 2023 | Tuesday | News
Image Source : Public Domain
"With the full upfront payment and other reimbursement from Gilead, we now have an even stronger balance sheet to advance development of products in our core therapeutic areas including the two blockbuster drugs, Nefecon and Xerava, expected to be commercialized in China later this year," said Ian Woo, President and Chief Financial Officer of Everest Medicines. "We will also utilize our resources to drive internal R&D as well as strategic business development."
Under the agreement reached with Immunomedics in August 2022, Everest is entitled to receive up to $455 million in total considerations with $280 million in upfront payments and up to $175 million in potential future milestone payments.
The company has approximately $430 million in pro forma cash and is expected to make the transition from a clinical-stage biotech to a fully-integrated biopharma this year with key milestones anticipated in core therapeutic areas of focus including renal disease, mRNA platform, and infectious diseases.